Clicky

Rhythm Pharmaceuticals, Inc.(RYTM)

Description: Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity. Setmelanotide serves as replacement therapy for the treatment of melanocortin-4, or MC4, pathway deficiencies. MC4 pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to intense feelings of hunger and to obesity. The Company also focused on obesity related to six single gene-related, or monogenic, MC4 pathway deficiencies pro-opiomelanocortin, or POMC, leptin receptor, or LepR, Bardet-Biedl syndrome, Alstrom syndrome, POMC heterozygous, and POMC epigenetic disorders.


Keywords: Biopharmaceutical Organ Systems Obesity Peptides Metabolic Disorders Peptide Hormones Genetic Disorder Monogenic Melanocortin Neuropeptides Bardet Biedl Syndrome Ciliopathy Homeostasis Leptin Pomc Epigenetic Disorders Proopiomelanocortin Setmelanotide

Home Page: www.rhythmtx.com

RYTM Technical Analysis

222 Berkeley Street
Boston, MA 02116
United States
Phone: 857 264 4280


Officers

Name Title
Dr. David P. Meeker M.D. Chairman, Pres & CEO
Mr. Hunter C. Smith M.B.A. CFO & Treasurer
Mr. Joseph Shulman Chief Technical Officer
Mr. Yann Mazabraud Exec. VP & Head of International
Ms. Jennifer L. Chien Exec. VP & Head of North America
Mr. William T. Roberts Chief Accounting Officer
Mr. David Connolly Head of Investor Relations & Corp. Communications
Mr. Jim Flaherty Sr. VP & Gen. Counsel
Ms. Sarah Ryan VP of Sales & Marketing
Ms. Pamela J. Cramer Chief HR Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 5.0137
Price-to-Sales TTM: 95.689
IPO Date: 2017-10-05
Fiscal Year End: December
Full Time Employees: 140
Back to stocks